Format

Send to

Choose Destination
Ann N Y Acad Sci. 2009 Sep;1174:61-7. doi: 10.1111/j.1749-6632.2009.04931.x.

Harnessing CD1d-restricted T cells toward antitumor immunity in humans.

Author information

1
Section of Hematology, Yale University, New Haven, CT 06510, USA.

Abstract

Natural killer T (NKT) cells are a distinct subset of T cells that recognize lipid antigens in the context of CD1d molecules. There is a considerable body of evidence implicating a role for NKT cells in regulating antitumor immunity in mice. alpha-Galactosylceramide (alpha-GalCer) is a potent agonist ligand for type I NKT cells. We and others have shown that injection of alpha-GalCer-loaded dendritic cells leads to clear expansion of NKT cells in vivo in cancer patients. Preclinical studies suggest the capacity of thalidomide analogues to enhance ligand-dependent NKT activation and provide the rationale for combination approaches that are now being designed. Recently, we demonstrated the presence of CD1d-restricted T cells specific for an inflammation-associated lipid, lysophosphatidylcholine, in patients with advanced myeloma. These studies suggest that type II NKT cells may play a role in sensing and regulating inflammation. Harnessing CD1d-restricted T cells in cancer may depend on regulating the balance between type I and II NKT cells and holds promise as a broad strategy for immune therapy of several cancers.

PMID:
19769737
PMCID:
PMC2782771
DOI:
10.1111/j.1749-6632.2009.04931.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center